Kittisak Kaewchalon/iStock via Getty Images
Vaccine cellNASDAQ:PCVX) stocks Added ~32% Pfizer announced Tuesday that it will market its experimental VAX-31 pneumococcal vaccine (PCV) after it showed a similar safety profile to Pfizer’s (NYSE:PFE) A competitor shot Prevnar 20 in a Phase 1/2 trial.
Based on preliminary data from the study, the company VAX-31 at all doses was well tolerated over a six-month evaluation period, similar to Prevnar 20, the researchers said. More than 1,000 healthy adults aged 50 and older participated in the study.
In terms of immunogenicity, the candidate vaccine demonstrated OPA-mediated immune responses against 31 bacterial serotypes. However, compared to PCV20, the median OPA-mediated immune responses were higher for 18 of 20 serotypes at the high dose of VAX-31.
Based on the results, Vaxcyte (PCVX) intends to advance the candidate, the broadest-spectrum PCV vaccine candidate in the clinic, into a Phase 3 adult program.
The pivotal Phase 3 study is expected to begin in mid-2025, with preliminary data planned for 2025. The company expects to begin the remaining Phase 3 trials in 2025 and 2026 to prepare for a marketing application for the candidate.